Allurion announces publication of randomized, double-blind study demonstrating significant improvement in obesity-related co-morbidities

Natick, mass.--(business wire)---- $alur #allurion--allurion technologies, inc. (nyse: alur), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in obesity surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the allurion program. these results improved with the addition of oral glp-1 agonist semaglutide. in the study, 115 patients were randomized to either the allurion program with.
ALUR Ratings Summary
ALUR Quant Ranking